P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL

Geahča maid

• P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL
  Dahkki: Nizar J Bahlis, et al.
  Almmustuhtton: (2023-08-01)
• S216: CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1, OPEN-LABEL STUDY
  Dahkki: J.-M. Michot, et al.
  Almmustuhtton: (2022-06-01)
• Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon
  Dahkki: Xiaolei Ma, et al.
  Almmustuhtton: (2023-12-01)
• Perspectives for the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma
  Dahkki: Sergei Vyacheslavovich Semochkin
  Almmustuhtton: (2023-06-01)
• Cereblon: A promising E3 ligase for broad-spectrum anticancer PROTAC drug development?
  Dahkki: Wenxin Fang, et al.
  Almmustuhtton: (2023-10-01)